tradmap

NDRA ENDRA Life Sciences Inc.

$4.80 -0.62%

Data as of close

Healthcare · Electromedical & Electrotherapeutic Apparatus

ENDRA Life Sciences Inc. (NDRA) is a healthcare company in the Electromedical & Electrotherapeutic Apparatus industry, with a market capitalization of $7 million. Shares last traded at $4.80, 30.0% below their 52-week high. Over the past year the stock is down 35.5%.

Market Cap
$7M
Shares Out
1.5M
EPS (TTM)
-$6.39
P/E (TTM)*
—
P/S Ratio
—
P/B Ratio
1.14
Dividend / Share
—
Dividend Yield
—
52-Week High
$6.86
52-Week Low
$2.97
Volume (venue)
50
Avg Vol (3m, venue)
553.921

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
+0.63%
1M
-22.58%
3M
+11.24%
6M
-6.07%
YTD
+8.35%
1Y
-35.48%

Daily candles · volume · SMA(20)/SMA(50) · split-adjusted · Databento EQUS.MINI. NDRA split history →

Technicals

RSI (14)
42.62
SMA (50)
$5.46
SMA (200)
$4.80
Price vs SMA50
-12.12%
Price vs SMA200
-0.01%
ATR (14)
$0.20

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
—
Net Income
-$6M
Gross Margin
—
Operating Margin
—
Net Margin
—
Return on Equity
-93.8%
Return on Assets
-74.5%
Current Ratio
7.10
Debt / Equity
0.00
Revenue Growth (YoY)
—

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $0.06 2026-08-14
Q1 2026 -$1.09 2026-05-15
Q4 2025 (derived) -$3.26 2026-03-31
FY 2025 -$8.93 2026-03-31
Q3 2025 -$2.10 2025-11-14
Q2 2025 -$1.71 —

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Electromedical & Electrotherapeutic Apparatus peers

NDRA vs 14 industry peers (Electromedical & Electrotherapeutic Apparatus), by market cap. Data as of close

1–14 of 14
MDTMedtronic$134.4B25.693.5813.9%+6.22%
LIVNLivanova Plc$5.2B26.473.4413.0%+17.67%
ITGRInteger Holdings Corp$4.3B41.522.365.7%+0.02%
AXGNAxogen, Inc.$3.1B—11.49-12.0%+3.67%
TMDXTransmedics Group, Inc.$2.5B16.623.7722.7%+7.85%
CNMDConmed Corp$1.6B34.011.163.4%+13.41%
CBLLCeribell, Inc.$1.1B—9.76-68.0%-3.50%
INMDInmode Ltd.$899M9.582.4325.3%+0.67%
CVCapsoVision, Inc$345M———+2.91%
ELMDElectromed, Inc.$234M20.703.1715.3%+4.25%
FOCLEDAP TMS SA$161M—2.28-41.5%-0.46%
VANIVivani Medical, Inc.$97M———+1.42%
STXSStereotaxis, Inc.$96M—3.18-74.2%+12.13%
NRXSNeuraxis, INC$86M———+2.94%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.